METHODS AND TREATMENT FOR CERTAIN DEMYELINATION AND DYSMYELINATION-BASED DISORDERS AND/OR PROMOTING REMYELINATION

(19)

(11)

EP 2 994 146 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.05.2021 Bulletin 2021/20

(45)	Mention of the grant of the patent:
	03.03.2021 Bulletin 2021/09

(21)	Application number: 14794569.5

(22)	Date of filing: 08.05.2014

(51)

International Patent Classification (IPC):

A61K 33/24^(2019.01)
A61K 9/16^(2006.01)
A61P 3/06^(2006.01)
A61P 25/00^(2006.01)
A61P 25/04^(2006.01)
A61P 27/02^(2006.01)

A61K 9/14^(2006.01)
A61K 9/10^(2006.01)
A61P 21/04^(2006.01)
A61P 25/02^(2006.01)
A61P 25/28^(2006.01)
A61P 43/00^(2006.01)

(86)	International application number:
	PCT/US2014/037280

(87)	International publication number:
	WO 2014/182888 (13.11.2014 Gazette 2014/46)

(54)

METHODS AND TREATMENT FOR CERTAIN DEMYELINATION AND DYSMYELINATION-BASED DISORDERS AND/OR PROMOTING REMYELINATION

VERFAHREN UND BEHANDLUNG FÜR BESTIMMTE DEMYELISIERUNGS- UND DYSMYELINIERUNGS-VERMITTELTE ERKRANKUNGEN UND ODER ZUR REMYELINISIERUNGSFÖRDERUNG

MÉTHODES ET TRAITEMENT POUR CERTAINS TROUBLES DE LA DÉMYÉLINISATION ET DE LA DYSMYÉLINISATION ET/OU POUR FAVORISER LA REMYÉLINISATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

08.05.2013 US 201361821040 P

(43)	Date of publication of application:
	16.03.2016 Bulletin 2016/11

(73)	Proprietors:
	Clene Nanomedicine, Inc. North East MD 21901 (US) Zhang, Zhongyan North East MD 21901 (US) Mortenson, Mark G. North East MD 21901 (US)

(72)	Inventors:
	ZHANG, Zhongyan North East, Maryland 21901 (US) MORTENSON, Mark G. North East, Maryland 21901 (US)

(74)	Representative: Harris, Oliver John Richard et al
	Novagraaf UK Centrum Norwich Research Park Colney Lane Norwich NR4 7UG Norwich NR4 7UG (GB)

(56)

References cited: :

WO-A1-2011/006007
WO-A2-2012/061828
US-A1- 2006 207 388
US-A1- 2008 266 555
US-A1- 2010 092 470

WO-A1-2011/006007
US-A1- 2006 068 026
US-A1- 2007 140 966
US-A1- 2009 169 807

DAN SONNE PEDERSEN ET AL: "Metallic gold slows disease progression, reduces cell death and induces astrogliosis while simultaneously increasing stem cell responses in an EAE rat model of multiple sclerosis", HISTOCHEMISTRY AND CELL BIOLOGY, SPRINGER, BERLIN, DE, vol. 138, no. 5, 22 July 2012 (2012-07-22) , pages 787-802, XP035124374, ISSN: 1432-119X, DOI: 10.1007/S00418-012-0996-2
FROHMAN E M ET AL: "MOST PATIENTS WITH MULTIPLE SCLEROSIS OR A CLINICALLY ISOLATED DEMYELINATING SYNDROME SHOULD BE TREATED AT THE TIME OF DIAGNOSIS", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 63, no. 4, 1 April 2006 (2006-04-01), pages 614-619, XP009072802, ISSN: 0003-9942, DOI: 10.1001/ARCHNEUR.63.4.614
ROMMER P S ET AL: "Monoclonal antibodies in the therapy of multiple sclerosis; An overview", JOURNAL OF NEUROLOGY, STEINKOPFF-VERLAG, DA, vol. 255, no. 6, 1 December 2008 (2008-12-01), pages 28-35, XP019714358, ISSN: 1432-1459
AKTAS O ET AL: "Neue therapeutische Konzepte bei der multiplen Sklerose /// Novel therapeutic strategies for multiple sclerosis - An overview", NERVENHEILKUNDE, SCHATTAUER, STUTTGART, DE, vol. 29, no. 5, 1 January 2010 (2010-01-01), pages 267-272, XP009182854, ISSN: 0722-1541

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).